Scott A. Wilke, MD, PhD, an assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health.

Linda Carpenter, MD, is a professor of psychiatry and human behavior at Brown University. 

This video features Linda Carpenter, MD, Professor of Psychiatry and Human Behavior at Brown University, Andrew Leuchter, MD, Professor and Director of the Neuromodulation Division at UCLA TMS Clinical and Research Services, and Scott Wilke, MD, PhD, Assistant Professor of Psychiatry and Penske Family Chair in Neuromodulation at UCLA Health, discussing accelerated TMS protocols, at-home brain stimulation, and new mechanistic data in the treatment of major depressive disorder. Topics include accelerated TMS for treatment-resistant depression, the 5x5 accelerated rTMS protocol, the SWIFT deep TMS protocol, theta burst stimulation, intermittent theta burst stimulation, deep TMS for MDD, ProlivRx FDA approval, at-home neuromodulation for major depressive disorder, the MOOD trial, physician-directed brain stimulation therapy, TMS insurance coverage, TMS reimbursement 2026, Medicare TMS coverage, TMS after antidepressant failure, prefrontal cortex neuromodulation, intratelencephalic neurons, personalized TMS treatment, TMS patient access, accelerated TMS efficacy, TMS vs conventional treatment, TMS clinical practice, treatment-resistant MDD, TMS psychiatry 2026, brain stimulation therapy for depression, noninvasive brain stimulation, repetitive transcranial magnetic stimulation, rTMS for depression, deep transcranial magnetic stimulation, TMS schedule, TMS protocol comparison, TMS outcomes, PHQ-9 TMS, HDRS TMS, TMS remission rates, TMS response rates, TMS delayed response, TMS maintenance, TMS and antidepressants, TMS adjunctive therapy, neuromodulation psychiatry, interventional psychiatry, brain stimulation MDD 2026.

 TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Transcranial magnetic stimulation (TMS) has been 

 since 2008, but for many patients with treatment-resistant depression (TRD), the traditional TMS treatment schedule has been the biggest obstacle to accessing it.

 The standard protocol requires 36 sessions, once daily, over 6 to 8 weeks, a commitment that costs patients their mornings, their commutes, and sometimes their jobs. For those living far from a TMS clinic, it has often meant no treatment at all.

In this video, 3 clinician-researchers, Linda Carpenter, MD, of Brown University; Andrew Leuchter, MD, of UCLA TMS Clinical and Research Services; and Scott Wilke, MD, PhD, Penske Family Chair in Neuromodulation at UCLA Health, walk through what is new in TMS for MDD and what it means for practicing psychiatrists treating patients who have not responded to antidepressants.

What New TMS Protocols for Treatment-Resistant Depression Mean for Clinical Practice

The clinical case for accelerated TMS protocols is building. A retrospective analysis published in March 2026 found that a

, 5 sessions per day over 5 consecutive days, produced efficacy comparable to the conventional 6-week TMS course.

 As Leuchter explained in an interview with 

, the compressed timeline has real implications for patient access and adherence, though insurance reimbursement for accelerated TMS approaches remains a significant gap.

—yet access barriers have limited TMS use in TRD for nearly 2 decades.

—a March 2026 retrospective analysis found comparable outcomes between 5x5 accelerated rTMS and the conventional 6-week daily course (

remission rates for ProlivRx vs sham in the MOOD trial (

 — Medicare reimburses up to 2 TMS sessions per day; accelerated protocols of 5 or more sessions per day remain unreimbursed as of 2026.

On the at-home neuromodulation front, the

 FDA approved Neurolief’s ProlivRx in January 2026

, the first prescription, physician-directed at-home brain stimulation therapy for MDD, indicated for adults who did not achieve satisfactory improvement from ≥ 1 prior antidepressant.

 Carpenter, who led the MOOD trial studying the device as adjunctive therapy, describes how the physician-directed model works in practice and what the current reimbursement landscape looks like for patients.

Wilke adds mechanistic context on how accelerated intermittent theta burst stimulation acts on specific cell types in the prefrontal cortex and what that could mean for personalizing TMS treatment for MDD.

For a deeper dive into the data behind each of these developments, read the full written feature here: 

TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home

Editor’s note: Reported disclosures include Neuronetics and Janssen Pharmaceuticals for Carpenter and Abbott Laboratories for Leuchter. Wilke has no reported disclosures.

Patel, P. The FDA Approved TMS For Treating Depression In 2008. TMS Institute of Arizona. Published May 13, 2025. 

https://tmsinstitute.co/the-fda-approved-tms-for-treating-depression-in-2008/

Leuchter A. Accelerated 5×5 rTMS Matches Standard Protocols in TRD, With Andrew Leuchter, MD. HCPLive. Published on March 24, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/accelerated-5-5-rtms-matches-standard-protocols-trd-andrew-leuchter-md

Derman C. Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days. HCPLive. Published on March 18, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/accelerated-deep-tms-matches-standard-outcomes-trd-6-days

Derman C. FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD. HCPLive. Published on January 13, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/fda-approves-proliv-rx-first-home-neuromodulation-mdd

Derman C. TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home. HCPLive. Published on May 15, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/tms-mdd-faster-fewer-visits-home

Videos

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Experts review standard diagnostic criteria for diabetes, then detail phenotypic and clinical features that support—but do not definitively confirm—a diagnosis of type 2 diabetes, emphasizing the limitations of BMI-based assumptions.

Beyond BMI: Clinical Features Supporting a True Type 2 Diabetes Diagnosis

In this portion of the discussion, Samson asks Umpierrez to walk through how the 2026 AACE classification algorithm helps confirm or question a diagnosis of type 2 diabetes in clinical practice. Umpierrez begins by reviewing that the biochemical thresholds used to diagnose diabetes—fasting plasma glucose of at least 126 mg/dL, 2-hour glucose of at least 200 mg/dL on oral glucose tolerance testing, hemoglobin A1c of at least 6.5%, or a random glucose of at least 200 mg/dL in the setting of hyperglycemic symptoms—apply to both type 1 and type 2 diabetes. These criteria, he notes, do not distinguish between etiologies but define the presence of diabetes itself.

To support a diagnosis of type 2 diabetes, Umpierrez outlines several clinical features that are commonly associated with this phenotype. These include overweight (body mass index [BMI] 25–29.9 kg/m²), obesity (BMI ≥30 kg/m²), a history of weight gain, prior gestational diabetes, a strong family history of type 2 diabetes, and physical examination findings of insulin resistance, such as acanthosis nigricans. He emphasizes acanthosis as one of the most important physical signs indicating significant insulin resistance. Samson and Umpierrez agree that these features can increase the likelihood of type 2 diabetes but must be interpreted within a broader clinical context.

However, both experts stress the limitations of relying on BMI alone. Umpierrez notes that BMI cutoffs are based on Western populations and may differ by race and ethnicity—for example, lower BMI thresholds in some Asian groups may better reflect cardiometabolic risk. He cites data from the adult-onset type 1 diabetes cohort discussed earlier, in which approximately 59% of patients with late-onset type 1 diabetes were overweight, and about 12% of adults with type 2 diabetes had a normal BMI. Samson and Umpierrez use these data to reinforce a key message of the 2026 AACE algorithm: although BMI and obesity are important clues, neither should be treated as definitive evidence of type 2 diabetes in adults with hyperglycemia.

Video Series

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.
Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include phase 3 data for roflumilast cream (Zoryve) in infants and older pediatric patients with 

 from the Revolutionizing Atopic Dermatitis 2026 Conference, 2-year data from the PATHFNDR open-label extensions confirming efficacy and safety of paltusotine (Palsonify) for acromegaly, a Diabetes Dialogue podcast discussion on pediatric advances in teplizumab, Dexcom Stelo, and inhaled insulin Afrezza, new data suggesting tirzepatide (Zepbound) improves kidney transplant eligibility in patients with 

 and CKD with severe obesity, and a feature on how prior authorization requirements are impacting dermatology practice and patient care.
With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of June 14, 2026 — let's jump in!

Phase 3 Data Indicate Roflumilast Cream Benefit Extends to Youngest Atopic Dermatitis Patients

A pair of poster presentations from the Revolutionizing Atopic Dermatitis 2026 Conference in Nashville, Tennessee, highlighted roflumilast cream (Zoryve) data across the pediatric age spectrum. In the INTEGUMENT-INFANT trial, roflumilast 0.05% cream applied once daily for 4 weeks in infants aged 3 to 24 months with mild-to-moderate atopic dermatitis (AD) achieved vIGA-AD treatment success in 49.0% of patients and EASI-75 in 67.5% at week 4. In a separate vehicle-controlled phase 3 trial of roflumilast 0.15% cream in patients aged ≥6 years, the agent produced numerically greater improvement than vehicle across all 4 EASI body regions and all 4 clinical signs from week 1 through week 4.

2-Year Paltusotine Data Confirms Efficacy, Safety for Acromegaly in Treatment-Naïve and SRL-Treated Patients

Presented at the Endocrine Society Annual Meeting 2026 in Chicago, Illinois, open-label extension data from the PATHFNDR-1 and PATHFNDR-2 trials showed paltusotine (Palsonify), a once-daily oral selective somatostatin receptor type 2 agonist, maintained biochemical and symptomatic control of acromegaly through 2 years in both SRL-switched and treatment-naïve patients. In PATHFNDR-1 (SRL-switched), mean IGF-1 levels were stable at 0.81x upper limit of normal at week 96. In PATHFNDR-2 (treatment-naïve), mean IGF-1 levels decreased from 1.64x ULN at baseline to 0.96x ULN at week 72. No new safety signals were identified across either extension.

Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients

In a recent Diabetes Dialogue episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed 3 pediatric diabetes milestones announced around the American Diabetes Association Scientific Sessions 2026. These include the expanded FDA indication for teplizumab in children and adolescents aged 8–17 years with newly diagnosed stage 3 type 1 diabetes, in which 95% of PROTECT trial participants maintained peak C-peptide levels above the study threshold at week 78; the FDA clearance of Dexcom Stelo as the first over-the-counter glucose biosensor for children aged ≥2 years not using insulin; and the pediatric approval of inhaled insulin (Afrezza) as an alternative to mealtime injections for children managing type 1 diabetes.

Tirzepatide (Zepbound) Improves Kidney Transplant Eligibility in T2D and CKD With Severe Obesity

Presented at the Endocrine Society Annual Meeting 2026, a poster from Angel Mary Joseph, MBBS, MD, MRCP, of Leeds Teaching Hospitals NHS Trust, showed tirzepatide (Zepbound) reduced mean BMI from 41.2 to 37.5 kg/m² and mean HbA1c from 61.9 to 52 mmol/mol over approximately 10 months in patients with type 2 diabetes, advanced CKD, and severe obesity who were ineligible for kidney transplant assessment due to elevated BMI. In total, 8 patients reached a BMI <35 kg/m², meeting the threshold for transplant assessment eligibility. Tirzepatide was well tolerated, with no reported severe hypoglycemia.

The Cost of Delay: How Prior Authorization Is Impacting Dermatology

 feature published this week interviewed 3 dermatologists — Harrison Nguyen, MD, MBA, MPH; Shannon Trotter, DO; and Matthew Zirwas, MD — about how prior authorization requirements, step therapy protocols, and formulary restrictions are affecting dermatology practice and patient access to biologics for conditions including atopic dermatitis, psoriasis, and hidradenitis suppurativa. All 3 clinicians described prior authorization as an escalating administrative burden, with step therapy delays potentially leaving patients without effective treatment for months. All three also agreed on the need for reform, citing greater formulary transparency, streamlined authorization processes, and restructured pharmacy benefit manager incentives as priority areas.

Articles

Pediatric atopic dermatitis data support once-daily topical roflumilast efficacy from infancy through older children, with early EASI and vIGA-AD improvements versus vehicle. Two-year PATHFNDR open-label extensions show sustained IGF-1 and symptom control with oral paltusotine in acromegaly, without new safety signals. Pediatric diabetes milestones include expanded teplizumab for stage 3 T1D, OTC Dexcom Stelo for non–insulin users ≥2 years, and pediatric inhaled insulin Afrezza. Tirzepatide lowered BMI/HbA1c, enabling kidney-transplant assessment eligibility in severe obesity with CKD. Dermatologists cite prior authorization and step-therapy delays limiting biologic access and prompting reform demands.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.
intro:

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 06/14

Javed Butler, MD, MBA
Credit: BAIM Institute

Albuminuria, measured as the urine albumin-to-creatinine ratio (UACR), is drawing renewed attention in cardiology as a marker that sits at the intersection of 

It rises before the glomerular filtration rate declines, making it an early signal of chronic kidney disease, and it also reflects systemic vascular endothelial dysfunction. Together, those properties position UACR as both an indirect cardiovascular risk factor, through chronic kidney disease, and a direct marker of vascular disease.

The clinical case for measuring UACR in patients with or at risk for 

 parallels how cardiology absorbed lipids and blood pressure into routine practice. The therapies prescribed for early chronic kidney disease, including MRAs, SGLT2 inhibitors, GLP-1 receptor agonists, and ACE inhibitors, lower UACR and reduce the risk of developing heart failure. That overlap is an argument for folding UACR into routine risk assessment now, even before guideline-directed targets are established.

A more difficult question for cardiology is whether therapy should be titrated to a UACR goal.  In the most recent 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome, the organizations endorse both eGFR and UACR testing for characterizing chronic kidney disease and guiding treatment decisions. The nephrology community has adopted a target of a 30% reduction in UACR, but those trials have not been conducted in cardiology. Because there is no physiologic floor for albuminuria, unlike cholesterol, an open question remains whether a 30% reduction is sufficient or whether clinicians should drive UACR as low as possible. Many patients retain persistent albuminuria despite standard combination therapy.

, Javed Butler, MD, MPH, MBA, president of the Baylor Scott & White Research Institute and a heart failure trialist, discussed whether albuminuria warrants a conceptual shift in heart failure risk assessment, when to act on an elevated UACR, and whether it could become a therapeutic monitoring target in future trials.

Q&A: Javed Butler, MD, MBA, on the Evolving Role of Albuminuria 

HCPLive: Does the emerging evidence justify a conceptual shift in how we approach heart failure and albuminuria measurement in these patients? And if so, do you agree this should be included in routine risk assessment in heart failure?

 The challenge that always comes up is risk factor versus risk marker. We have a lot of risk factors in cardiology, so how do we decide which tests to add? Historically, remember that at one point cardiologists had nothing to do with lipids. It was an endocrine disease until we found that lipids were associated with cardiovascular outcomes, and that lipid modulation was associated with improved outcomes, and now it is bread-and-butter cardiology. Hypertension used to be a nephrology disease, and now you obviously cannot go to a cardiologist's office and not get your blood pressure checked.

So if you look at the data with UACR, the reason it modulates cardiovascular risk is, one, that it is an earlier marker of chronic kidney disease, even before the GFR goes down; and two, that it is a marker of systemic vascular endothelial dysfunction. Hence it is a risk factor for cardiovascular disease indirectly, through CKD, and directly, as a marker of vascular disease. In my opinion, at least, the data are strong enough that when UACR goes up and you start giving the therapies you would give to patients with early CKD, all of those therapies reduce the risk of developing heart failure. For that reason alone, cardiology should do it now.

What if you already have heart failure and you are going to give heart failure therapies? Do you still need to do it? Now we are not talking about the risk going up, but about whether therapy should be targeted to UACR. You give somebody standard therapy and you measure the UACR, but it is still high. Should you then give even higher doses or add more medication? That part of the equation we have not solved just yet. But in terms of identifying high-risk patients and early targeting of comprehensive therapy, I think the data are pretty much there that UACR is a good marker, and I think the cardiology community will, hopefully, be embracing it.

HCPLive: When we talk about albuminuria, do you think the heart failure framework should begin treating it as early as possible? Or, in the absence of a guideline-directed approach, is this more of a fundamental limitation?

Let's break it down into a few component pieces. If you do not have heart failure, you are in general cardiology practice, and you are completely asymptomatic and otherwise doing well, you should check your hemoglobin A1C; if it is elevated, you need to be treated for diabetes. You should measure cholesterol; if it is elevated, you should be treated for dyslipidemia. I think you should develop the same mindset that you should check the UACR, and if it is elevated, you have CKD, and it needs to be treated with appropriate therapy to reduce cardiovascular risk. That is one bucket, about prevention.

The second bucket is the heart failure patient. Even if you adjust for other risk factors, if the UACR is substantially elevated, then close follow-up and aggressive management are important.

But the third part, which you are specifically asking about, is probably the most important question: whether, as with lipids, we should titrate therapy to a target. With lipids, we have the LDL, we start therapy, but we do not stop there; we titrate therapy to get the lipid to a certain level. Should we be titrating therapy to get UACR to a certain level? There is a lot of interest in it. In the nephrology community, they have set a target of a 30% reduction in UACR. We have not done those trials in cardiology just yet.

HCPLive: If albuminuria is both predictive and modifiable, do you foresee it becoming a core therapeutic monitoring target in future heart failure trials? And if so, why or why not?

Here is my best prediction. The nephrology community right now is a little bit divided over whether everybody should get all the therapies, or whether, if somebody responds very favorably to UACR reduction with, say, two medicines, you really need the third or the fourth. In the cardiology community, we have a slightly different orientation right now, in that pretty much everybody believes in combination therapy. The combination therapy we give to patients includes MRA, SGLT2 inhibitor, aldosterone synthase inhibitor (possibly coming down the pike), GLP-1 receptor agonist (possibly coming down the pike), and ACE inhibitors, and all of these therapies reduce UACR. So if you go with the target of a 30% reduction, I think with standard therapy you will probably find that most patients get there anyway, and that this becomes a moot point.

The question that comes up is that, unlike cholesterol, where a certain degree of cholesterol is needed for us to live, UACR is different. For cholesterol, the right number is not zero; it is quite low, but not zero. For UACR, there is no right number. You should not be leaking protein at all. So should we be satisfied with a 30% reduction in UACR, or should we really try to drive it as far down as possible? That science has not been done. I can bet you that even on standard therapy, there are a lot of patients who have a substantial reduction but still have persistent albuminuria, and what to do about that is maybe something we should work on for the next 10 years.

This transcript has been edited for grammar and clarity using artificial intelligence tools. 


Butler J, Jamil A, Cherney DZI, Jafar TH, Testani JM, Khan MS. Albuminuria and heart failure. 

. Published online June 12, 2026. doi:10.1093/eurheartj/ehag426 

Writing Committee Members, Ndumele CE, Rodriguez F, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 

. Published online June 9, 2026. doi:10.1161/CIR.0000000000001453

Urine albumin-to-creatinine ratio (UACR) is re-emerging as an actionable cardio–renal biomarker that rises before eGFR decline and reflects systemic endothelial dysfunction. These features link albuminuria to heart failure risk both indirectly via early CKD and directly as vascular disease biology. Broad cardiometabolic therapies—MRAs, SGLT2 inhibitors, ACE inhibitors, and emerging GLP-1 RAs/aldosterone synthase inhibitors—reduce UACR and lower incident HF risk, supporting routine incorporation into risk assessment. Whether to titrate therapy to UACR targets remains unresolved.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Chronic Kidney Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

The Value of Albuminuria in Heart Failure Risk Assessment, with Javed Butler, MD, MBA

Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

Javed Butler, MD, MBA, on Aldosterone & Aldosterone Synthase Inhibitors in Cardiology

Aldosterone is drawing renewed scientific attention as a treatment target across 

. A new generation of aldosterone synthase inhibitors aims to lower aldosterone production directly, rather than blocking its receptor.

, Javed Butler, MD, MBA, president of the Baylor Scott & White Research Institute, examined where this approach fits in cardiorenal care. He weighed the evidence behind aldosterone synthase inhibition and its potential role in guideline-directed medical therapy for heart failure.

Recapping a session he led at the meeting, Butler emphasized how earlier aldosterone modulation data came largely from heart failure with reduced ejection fraction, along with post-myocardial infarction trials in reduced ejection fraction and heart failure. Noting evidence in chronic kidney disease and in prevention lagged, and findings in heart failure with preserved ejection fraction were contested.

Butler highlighted the unresolved question remains whether the aldosterone hypothesis itself is flawed or whether current receptor-targeted therapies leave meaningful residual benefit unharnessed. Lowering aldosterone levels directly through synthase inhibition offers a way to test the second possibility.

When asked on choosing between mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, Butler highlighted this debate remains unsettled until further trial data becomes available. He called attention to earlier MRA trials enrolling few patients on SGLT2 inhibitors or GLP-1 receptor agonists, whereas the synthase inhibitor trials use active comparators in which every participant receives an SGLT2 inhibitor.

ClinicalTrials.Gov. A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA). Clinicaltrials.gov. Published February 18, 2026. Accessed June 21, 2026. https://clinicaltrials.gov/study/NCT06299826 

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Podcasts

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Q&A: What Are the Most Exciting New Atopic Dermatitis Developments? With Mona Shahriari, MD

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Yale Study: Two-Thirds of Online GLP-1 Prescriptions Require No Clinician-Patient Interaction

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

What is the Most Contested Issue in Atopic Dermatitis Today? With Mona Shahriari, MD

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema. 

Delgocitinib Cream Shows Consistent CHE Efficacy Across Several Subgroups

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Latest News

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Beyond BMI: Clinical Features Supporting a True Type 2 Diabetes Diagnosis

The HCPFive: Top News for Healthcare Providers from the Week of 06/14

The Value of Albuminuria in Heart Failure Risk Assessment, with Javed Butler, MD, MBA

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA